

Study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)

Submission date 02/03/2012	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/03/2012	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 23/05/2025	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Current plain English summary as of 13/02/2019:

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-selumetinib-people-kaposi-sarcoma-scart>

Previous plain English summary:

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-selumetinib-people-kaposi-sarcoma-scart>

Contact information

Type(s)

Scientific

Contact name

Dr Robin Young

Contact details

Weston Park Hospital

Sheffield

United Kingdom

S10 2SJ

0114 226 5000

r.j.young@sheffield.ac.uk

Type(s)

Scientific

Contact name

Dr Joshua Savage

ORCID ID

<https://orcid.org/0000-0003-0599-0245>

Contact details

Early Drug Development Team Leader
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
+44 (0)121 415 8421
j.savage.1@bham.ac.uk

Type(s)

Public

Contact name

Dr SCART Team

Contact details

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
+44 (0) 121 414 6754
scart@contacts.bham.ac.uk

Additional identifiers**ClinicalTrials.gov (NCT)**

NCT01752569

Clinical Trials Information System (CTIS)

2011-003099-35

Protocol serial number

11876

Study information

Scientific Title

Phase I/II study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)

Acronym

SCART

Study objectives

Cancer is a leading cause of death in individuals living with HIV, and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer. KS results from co-infection with HIV and another virus, HHV-8. Laboratory studies have shown that HHV-8 viral proteins stimulate intracellular signalling pathways within KS lesions which promotes their growth. Selumetinib targets these signalling pathways and may therefore be a useful new therapy for KS.

SCART is a national multi-centre study. The objectives of the SCART trial are to determine a safe and tolerable dose for selumetinib in combination with HIV anti-retroviral therapy, and to determine whether selumetinib reduces KS lesions in HIV positive patients.

More details can be found at <http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11876> (link no longer works as of 13/02/2019)

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 10/11/2011, Yorkshire and the Humber - Leeds East (NHSBT Newcastle Blood Donor Centre
Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 1048171, (0)207 104 8141;
leedseast.rec@hra.nhs.uk), ref: 11/YH/0373

Study design

Non-randomized interventional study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Sarcoma

Interventions

Selumetinib, Orally bioavailable, selective inhibitor of MEK 1/2, inhibiting the phosphorylation of ERK 1/2

Patients will undergo 6 x 21-day (3-weekly) cycles of treatment. There is a screening visit following by visits every at the end of every cycle. In Phase I during cycle 1 there are weekly visits. Visits involve clinical examination, periodic clinical photographs of lesions, haematology /biochemistry, blood samples taken for translational studies. CT, ECHO or Multi Gated Acquisition Scan (MUGA). Ophthalmologic exam will occur during screening. Further

assessments of this nature will only be performed if judged clinically necessary. Patients will have a follow-up visit every 12 weeks for 12 months to record changes in lesions by clinical photographs.

Intervention Type

Drug

Phase

Phase I/II

Drug/device/biological/vaccine name(s)

Selumetinib

Primary outcome(s)

Objective response rates; Timepoint(s): Phase I and II

Key secondary outcome(s)

1. HAART Drug Levels; Timepoint(s): Phase I
2. HIV control; Timepoint(s): Phase I and II
3. Number of selumetinib cycles completed; Timepoint(s): Phase I and II
4. PBMC Sub-study; Timepoint(s): Phase I and II; PD measures of selumetinib in combination with HAART; Timepoint(s): Phase I and II
5. Progression free survival rate; Timepoint(s): Phase I and II - 6 months post completion of study
6. Selumetinib and metabolite serum levels; Timepoint(s): phase I
7. Toxicity; Timepoint(s): Phase I and II

Completion date

31/01/2018

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

1. Human immunodeficiency virus (HIV) positive and established on a HAART regimen for ≥ 3 months
2. Histologically confirmed KS
3. Measurable disease according to AIDS Clinical Trials Group (ACTG) criteria
4. Evidence of disease progression in the past 6 months, without anticancer treatment since progression
5. Progressive cutaneous or nodal KS not requiring chemotherapy or progressive KS following cytotoxic chemotherapy
6. Adequate haematological function:
 - 6.1. Haemoglobin = 9 g/dL
 - 6.2. Absolute neutrophil count = $1.5 \times 10^9/L$
 - 6.3. Platelets = $100 \times 10^9/L$
7. Adequate hepatic function:
 - 7.1. Serum bilirubin = 1.5 x upper limit of normal (ULN)

- 7.2. Alanine aminotransferase (ALT) = 2.5 x ULN
- 7.3. Aspartate aminotransferase (AST) = 2.5 x ULN
8. Adequate renal function:
 - 8.1. Serum creatinine clearance > 50 ml/min (Cockcroft-Gault formula or 24 hour urine collection)
 - 8.2. Left ventricular function >50% normal
9. Age = 18 years.
10. Eastern Cooperative Oncology Group (ECOG) performance status > 2
11. For selumetinib, women of child bearing age and child bearing potential must have a negative pregnancy test prior to study entry and be using an adequate contraception method, which must be continued while on treatment and for at least 4 weeks after the study treatment has ended
12. Male patients must agree to use an effective contraception method while on treatment and for at least 16 weeks after the study treatment has ended (barrier contraception is recommended for all individuals living with HIV).
13. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

19

Key exclusion criteria

1. HIV viral load > 200 copies/ml
2. Any previous treatment with a Ras, Raf or MEK inhibitor
3. Active opportunistic infections.
4. Known hepatitis B, hepatitis C
5. Clinical evidence of uncontrolled hypertension (systolic BP > 150 mmHg or diastolic BP > 90 mmHg on 2 readings = 1 hour apart))
6. Clinical evidence of heart failure (= New York Heart Association [NYHA] Class II)
7. Clinical evidence of atrial fibrillation (heart rate > 100 bpm) or unstable ischaemic heart disease (MI within 6 months prior to starting treatment or angina requiring the use of nitrates > once weekly)
8. Major surgery within 4 weeks prior to starting selumetinib
9. Evidence of any psychological, familial, sociological or geographical condition potentially hampering protocol compliance
10. Clinical judgement by the Investigator that the patient should not participate in the study
11. Refractory nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption

12. Treatment with any investigational product within 28 days of registration

13. Pregnant or breastfeeding women

Date of first enrolment

12/03/2012

Date of final enrolment

31/12/2016

Locations

Countries of recruitment

United Kingdom

England

Scotland

Study participating centre

Weston Park Hospital

Whitham Road

Sheffields

United Kingdom

S10 2SJ

Study participating centre

Royal Free London NHS Foundation Trust Royal Free Hospital

Pond Street

London

United Kingdom

NW3 2QG

Study participating centre

Royal Sussex County Hospital

Eastern Road

Brighton

United Kingdom

BN2 5BE

Study participating centre

Chelsea and Westminster NHS Foundation Trust

369 Fulham Road

London

United Kingdom
SW10 9NH

Study participating centre
Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow
United Kingdom
G12 0YN

Study participating centre
Christie Hospital
Wilmslow Road
Manchester
United Kingdom
M20 4BX

Sponsor information

Organisation
Sheffield Teaching Hospitals NHS Trust (UK)

ROR
<https://ror.org/018hjpz25>

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK (CRUK) (UK)

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Current IPD sharing statement as of 01/02/2023:

The datasets generated during and/or analysed during the current study are/will be available upon request. Scientifically sound proposals from appropriately qualified researchers will be considered for data sharing. Requests should be made by returning a Data Sharing Request Form to newbusiness@trials.bham.ac.uk; this captures the research requirements, statistical analysis plan, and intended publication schedule. Requests will be reviewed by the Cancer Research UK Clinical Trials Unit (CRCTU) Directors in discussion with the Chief Investigator (CI), Trial Management Group (TMG), independent Data Monitoring Committee (DMC) and Sponsor (Sheffield Teaching Hospitals NHS Foundation Trust). They will consider the scientific validity of the request, qualifications of the researchers, CI, TMG & TSC views, consent arrangements, the practicality of anonymizing the requested data and contractual obligations. If supportive of the request, and where not already obtained, Sponsor consent for data transfer will be sought before notifying applicants of the outcome. It is anticipated that applicants will be notified within 3 months of receipt of the original request.

Previous IPD sharing statement:

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		19/03/2025	25/03/2025	Yes	No
Basic results	version 1.0a	16/02/2023	16/02/2023	No	No
HRA research summary			28/06/2023	No	No
Plain English results			23/05/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes